Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference

Cancer Letters

Volumn 380, Issue 2, 2016, Pages 525-533

  Biel, Nikolett M ^a   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Ang 2 targeting; Angiogenesis; Anti angiogenic therapy; Combination therapy; VEGF targeting

Indexed keywords

AFLIBERCEPT; AMG 780; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CVX 060; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEDI 3617; MITOGEN ACTIVATED PROTEIN KINASE; NESVACUMAB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; ANGIOGENESIS INHIBITOR; ANGPT2 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

BINDING AFFINITY; CANCER GROWTH; CANCER RADIOTHERAPY; CARCINOGENESIS; COLORECTAL CANCER; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SARCOMA; SHORT SURVEY; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; THYROID MEDULLARY CARCINOMA; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-2; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84923003376     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.035     Document Type: Review

References (134)

1. [1] Papetti, M., Herman, I.M., Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol 282 (2002), C947–C970.
2. [2] Folkman, J., Angiogenesis: an organizing principle for drug discovery?. Nat. Rev. Drug Discov 6 (2007), 273–286.
3. [3] Folkman, J., Tumor angiogenesis: therapeutic implications. N. Engl. J. Med 285 (1971), 1182–1186.
4. [4] Denekamp, J., Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br. J. Cancer 45 (1982), 136–139.
5. [5] Denekamp, J., Vascular endothelium as the vulnerable element in tumours. Acta Radiol 23 (1984), 217–225.
6. [6] Young, R.J., Reed, M.W., Anti-angiogenic therapy: concept to clinic. Microcirculation 19 (2012), 115–125.
7. [7] Meadows, K.L., Hurwitz, H.I., Anti-VEGF therapies in the clinic. Klagsburn, M., D'Amore, P., (eds.) Perspectives in Medicine, 2012, Cold Spring Harbor Laboratory Press, New York, 1–27.
8. [8] McDonald, D.M., Angiogenesis and vascular remodeling in inflammation and cancer: biology and architecture of the vasculature. Folkman, J., Figg, W.D., (eds.) Angiogenesis: an Integrative Approach from Science to Medicine, 2008, Springer, New York.
9. [9] Vaupel, P., Abnormal microvasculature and defective microcirculatory function in solid tumors. Siemann, D.W., (eds.) Vascular Targeted Therapies in Oncology, 2006, Wiley Ltd, West Sussex, UK.
10. [10] Minchinton, A.I., Kyle, A.H., Drug penetration and therapeutic resistance. Siemann, D.W., (eds.) Tumor Microenvironment, 2011, Wiley-Blackwell Ltd, West Sussex, UK.
11. [11] Minchinton, A.I., Tannock, I.F., Drug penetration in solid tumours. Nat. Rev 6 (2006), 583–592.
12. [12] Bergers, G., Hanahan, D., Modes of resistance to anti-angiogenic therapy. Nat. Rev 8 (2008), 592–603.
13. [13] Ebos, J.M., Lee, C.R., Kerbel, R.S., Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin. Cancer Res 15 (2009), 5020–5025.
14. [14] Partanen, J., Armstrong, E., Makela, T.P., Korhonen, J., Sandberg, M., Renkonen, R., et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol. Cell. Biol 12 (1992), 1698–1707.
15. [15] Davis, S., Aldrich, T.H., Jones, P.F., Acheson, A., Compton, D.L., Jain, V., et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87 (1996), 1161–1169.
16. [16] Schnurch, H., Risau, W., Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 119 (1993), 957–968.
17. [17] Valenzuela, D.M., Griffiths, J.A., Rojas, J., Aldrich, T.H., Jones, P.F., Zhou, H., et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 96 (1999), 1904–1909.
18. [18] Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand, S.J., Radziejewski, C., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997), 55–60.
19. [19] Augustin, H.G., Koh, G.Y., Thurston, G., Alitalo, K., Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol 10 (2009), 165–177.
20. [20] Thomas, M., Augustin, H.G., The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 12 (2009), 125–137.
21. [21] Loughna, S., Sato, T.N., Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 20 (2001), 319–325.
22. [22] Molnar, N., Siemann, D.W., Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617. Microvasc. Res 83 (2012), 290–297.
23. [23] Saharinen, P., Eklund, L., Miettinen, J., Wirkkala, R., Anisimov, A., Winderlich, M., et al. Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Nat. Cell Biol 10 (2008), 527–537.
24. [24] Fukuhara, S., Sako, K., Minami, T., Noda, K., Kim, H.Z., Kodama, T., et al. Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat. Cell Biol 10 (2008), 513–526.
25. [25] Gavard, J., Patel, V., Gutkind, J.S., Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev. Cell 14 (2008), 25–36.
26. [26] Hayashi, M., Majumdar, A., Li, X., Adler, J., Sun, Z., Vertuani, S., et al. VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation. Nat. Commun, 4, 2013, 1672.
27. [27] Fujikawa, K., de Aos Scherpenseel, I., Jain, S., Presman, E., Varticovski, L., The role of PI3-Kinase in Angiopoietin-1-mediated migration and attachment-dependent survival of endothelial cells. Exp. Cell Res 253 (1999), 663–672.
28. [28] Kim, I., Kim, H., So, J., Kim, J., Kwak, H., Koh, G., Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Circ. Res 86 (2000), 24–29.
29. [29] Hughes, D., Marron, M., Brindle, N., The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2. Circ. Res 92 (2003), 630–636.
30. [30] Fiedler, U., Scharpfenecker, M., Koidl, S., Hegen, A., Grunow, V., Schmidt, J.M., et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 103 (2004), 4150–4156.
31. [31] Huang, Y.Q., Li, J.J., Hu, L., Lee, M., Karpatkin, S., Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 99 (2002), 1646–1650.
32. [32] Dixit, M., Bess, E., Fisslthaler, B., Hartel, F.V., Noll, T., Busse, R., et al. Shear stress-induced activation of the AMP-activated protein kinase regulates FoxO1a and angiopoietin-2 in endothelial cells. Cardiovasc. Res 77 (2008), 160–168.
33. [33] Jang, C., Koh, Y.J., Lim, N.K., Kang, H.J., Kim, D.H., Park, S.K., et al. Angiopoietin-2 exocytosis is stimulated by sphingosine-1-phosphate in human blood and lymphatic endothelial cells. Arterioscler. Thromb. Vasc. Biol 29 (2009), 401–407.
34. [34] Scharpfenecker, M., Fiedler, U., Reiss, Y., Augustin, H.G., The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J. Cell Sci 118 (2005), 771–780.
35. [35] Gale, N.W., Thurston, G., Hackett, S.F., Renard, R., Wang, Q., McClain, J., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev. Cell 3 (2002), 411–423.
36. [36] Suri, C., Jones, P.F., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87 (1996), 1171–1180.
37. [37] Sato, T.N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376 (1995), 70–74.
38. [38] Song, S.H., Kim, K.L., Lee, K.A., Suh, W., Tie1 regulates the Tie2 agonistic role of angiopoietin-2 in human lymphatic endothelial cells. Biochem. Biophys. Res. Commun 419 (2012), 281–286.
39. [39] Seegar, T.C., Eller, B., Tzvetkova-Robev, D., Kolev, M.V., Henderson, S.C., Nikolov, D.B., et al. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol. Cell 37 (2010), 643–655.
40. [40] Hansen, T., Singh, H., Tahir, T., Brindle, N., Effects of Angiopoietin-1 and -2 on the receptor tyrosine kinase Tie2 are differentially regulated at the endothelial cell surface. Cell. Signal 22 (2010), 527–532.
41. [41] Kim, K.L., Shin, I.S., Kim, J.M., Choi, J.H., Byun, J., Jeon, E.S., et al. Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells. Cardiovasc. Res 72 (2006), 394–402.
42. [42] Brown, L.F., Dezube, B.J., Tognazzi, K., Dvorak, H.F., Yancopoulos, G.D., Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am. J. Pathol 156 (2000), 2179–2183.
43. [43] Yu, X., Seegar, T.C., Dalton, A.C., Tzvetkova-Robev, D., Goldgur, Y., Rajashankar, K.R., et al. Structural basis for angiopoietin-1-mediated signaling initiation. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 7205–7210.
44. [44] Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F., Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983), 983–985.
45. [45] Ferrara, N., Henzel, W.J., Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun 161 (1989), 851–858.
46. [46] Ferrara, N., Gerber, H.P., LeCouter, J., The biology of VEGF and its receptors. Nat. Med 9 (2003), 669–676.
47. [47] Shibuya, M., Vascular permeability/vascular endothelial growth factor. Folkman, J., Figg, W.D., (eds.) Angiogenesis: an Integrative Approach from Science to Medicine, 2008, Springer Science + Business Media, LLC, New York.
48. [48] Gerber, H.P., Dixit, V., Ferrara, N., Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem 273 (1998), 13313–13316.
49. [49] Gerber, H.P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B.A., Dixit, V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3’-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem 273 (1998), 30336–30343.
50. [50] Carmeliet, P., Lampugnani, M.G., Moons, L., Breviario, F., Compernolle, V., Bono, F., et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98 (1999), 147–157.
51. [51] Dejana, E., Spagnuolo, R., Bazzoni, G., Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thromb. Haemost 86 (2001), 308–315.
52. [52] Takahashi, T., Ueno, H., Shibuya, M., VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18 (1999), 2221–2230.
53. [53] Figg, W., Folkman, J., Angiogenesis: an Integrative Approach from Science to Medicine. 2008, Springer Science + Business Media, LLC, New York, 591.
54. [54] Klagsbrun, M., D'Amore, P., Angiogenesis: Biology and Pathology. 2012, Cold Spring Harbor Laboratory Press, New York, 522.
55. [55] Ellis, L., Epidermal growth factor receptor in tumor angiogenesis. Hematol. Oncol. Clin. North Am 18 (2004), 1007–1021.
56. [56] De Luca, A., Carotenuto, A., Rachiglio, A., Gallo, M., Maiello, M., Aldinucci, D., et al. The role of EGFR signaling in tumor microenvironment. J. Cell. Physiol 214 (2008), 559–567.
57. [57] Carmeliet, P., Mechanisms of angiogenesis and arteriogenesis. Nat. Med 6 (2000), 389–395.
58. [58] Blanco, R., Gerhardt, H., VEGF and notch in tip and stalk cell selection. Klagsburn, M., Amore, P.A.D., (eds.) Angiogenesis: Biology and Pathology, 2012, Cold Spring Harbor Laboratory Press, New York, 41–59.
59. [59] Ferrara, N., Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21 (2010), 21–26.
60. [60] Lieu, C., Heymach, J., Overman, M., Tran, H., Kopetz, S., Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res 17 (2011), 6130–6139.
61. [61] Daniele, G., Corral, J., Molife, L.R., de Bono, J.S., FGF receptor inhibitors: role in cancer therapy. Curr. Oncol. Rep 14 (2012), 111–119.
62. [62] Yan, M., Plowman, G.D., Delta-like 4/Notch signaling and its therapeutic implications. Clin. Cancer Res 13 (2007), 7243–7246.
63. [63] Aster, J.C., Blacklow, S.C., Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J. Clin. Oncol 30 (2012), 2418–2420.
64. [64] Bais, C., Wu, X., Yao, J., Yang, S., Crawford, Y., McCutcheon, K., et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 141 (2010), 166–177.
65. [65] Bid, H.K., Zhan, J., Phelps, D.A., Kurmasheva, R.T., Houghton, P.J., Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol. Cancer Ther 11 (2012), 649–659.
66. [66] Wang, Y., Yao, X., Ge, J., Hu, F., Zhao, Y., Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systemic review and meta-analysis. ScientificWorldJournal, 2014, 2014, 102736.
67. [67] Zhan, P., Wang, J., Lv, X.J., Wang, Q., Qiu, L.X., Lin, X.Q., et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systemic review with meta-analysis. J. Thorac. Oncol 4 (2009), 1094–1103.
68. [68] Smith, R.A., Tang, J., Tudur-Smith, C., Neoptolemos, J.P., Ghaneh, P., Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br. J. Cancer 104 (2011), 1140–1151.
69. [69] Schoenleber, S.J., Kurtz, D.M., Talwalkar, J.A., Roberts, L.R., Gores, G.J., Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systemic review and meta-analysis. Br. J. Cancer 100 (2009), 1385–1392.
70. [70] Uzzan, B., Nicolas, P., Cucherat, M., Perret, G.Y., Microvessel density as a prognostic factor in women with breast cancer: a systemic review of the literature and meta-analysis. Cancer Res 64 (2004), 2941–2955.
71. [71] Chen, J., Li, T., Wu, Y., He, L., Zhang, L.C., Shi, T., et al. Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J. Cancer Res. Clin. Oncol 137 (2011), 1799–1812.
72. [72] Hanahan, D., Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996), 353–364.
73. [73] Charlesworth, P.J.S., Harris, A.L., Hypoxic regulation of angiogenesis by HIF-1. Folkman, J., Figg, W.D., (eds.) Angiogenesis: an Integrative Approach from Science to Medicine, 2008, Springer Science + Business Media, LLC, New York.
74. [74] Rankin, E.B., Giaccia, A.J., The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15 (2008), 678–685.
75. [75] Leung, D.W., Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989), 1306–1309.
76. [76] Bach, F., Uddin, F.J., Burke, D., Angiopoietins in malignancy. Eur. J. Surg. Oncol 33 (2007), 7–15.
77. [77] Molnar, N., Siemann, D.W., Angiopoietin-2 axis inhibitors: current status and future considerations for cancer therapy. Curr. Angiogenes 2 (2013), 2–12.
78. [78] Lind, A.J., Wikstrom, P., Granfors, T., Egevad, L., Stattin, P., Bergh, A., Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 62 (2005), 394–399.
79. [79] Helfrich, I., Edler, L., Sucker, A., Thomas, M., Christian, S., Schadendorf, D., et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin. Cancer Res 15 (2009), 1384–1392.
80. [80] Detjen, K.M., Rieke, S., Deters, A., Schulz, P., Rexin, A., Vollmer, S., et al. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin. Cancer Res 16 (2010), 420–429.
81. [81] Sie, M., Wagemakers, M., Molema, G., Mooij, J.J., de Bont, E.S., den Dunnen, W.F., The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J. Neurosurg 110 (2009), 147–155.
82. [82] Park, J.H., Park, K.J., Kim, Y.S., Sheen, S.S., Lee, K.S., Lee, H.N., et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 132 (2007), 200–206.
83. [83] De Palma, M., Naldini, L., Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin. Cancer Res 17 (2011), 5226–5232.
84. [84] Montero, A.J., Escobar, M., Lopes, G., Gluck, S., Vogel, C., Bevacizumab in the treatment of metastatic breast cancer: friend or foe?. Curr. Oncol. Rep 14 (2012), 1–11.
85. [85] Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med 350 (2004), 2335–2342.
86. [86] A. Pollack, F.D.A. Revokes Approval of Avastin for Use as Breast Cancer Drug, The New York Times, New York, 2011, p. B1.
87. [87] Siemann, D.W., The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat. Rev 37 (2011), 63–74.
88. [88] Horsman, M.R., Siemann, D.W., Pathophysiological effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66 (2006), 11520–11539.
89. [89] Kerbel, R.S., Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 312 (2006), 1171–1175.
90. [90] Bottsford-Miller, J.N., Coleman, R.L., Sood, A.K., Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J. Clin. Oncol 30 (2012), 4026–4034.
91. [91] Jain, R.K., Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 19 (2005), 7–16.
92. [92] Coxon, A., Bready, J., Min, H., Kaufman, S., Leal, J., Yu, D., et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol. Cancer Ther 9 (2010), 2641–2651.
93. [93] Falcón, B.L., Hashizume, H., Koumoutsakos, P., Chou, J., Bready, J.V., Coxon, A., et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am. J. Pathol 175 (2009), 2159–2170.
94. [94] Felcht, M., Luck, R., Schering, A., Seidel, P., Srivastava, K., Hu, J., et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J. Clin. Invest 122 (2012), 1991–2005.
95. [95] De Palma, M., Murdoch, C., Venneri, M.A., Naldini, L., Lewis, C.E., Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 28 (2007), 519–524.
96. [96] Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 19 (2011), 512–526.
97. [97] Loges, S., Schmidt, T., Carmeliet, P., Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1 (2010), 12–25.
98. [98] Zhang, Z.L., Zhang, J.F., Yuan, Y.F., He, Y.M., Liu, Q.Y., Mao, X.W., et al. Supression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody. Exp. Ther. Med 7 (2014), 543–552.
99. [99] D'Amico, G., Korhonen, E.A., Anisimov, A., Zarkada, G., Holopainen, T., Hagerling, R., et al. Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. J. Clin. Invest 124 (2014), 824–834.
100. [100] ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), Keyword “Ang-2”. Available from https://clinicaltrials.gov/ct2/results?term=Ang-2&Search=Search, 2000 accessed 2014 May 28.
101. [101] Daly, C., Eichten, A., Castanaro, C., Pasnikowski, E., Adler, A., Lalani, A.S., et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 73 (2013), 108–118.
102. [102] Leow, C.C., Coffman, K., Inigo, I., Breen, S., Czapiga, M., Soukharev, S., et al. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int. J. Oncol 40 (2012), 1321–1330.
103. [103] Doppalapudi, V.R., Huang, J., Liu, D., Jin, P., Liu, B., Li, L., et al. Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 22611–22616.
104. [104] Sitohy, B., Nagy, J.A., Dvorak, H.F., Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res 72 (2012), 1909–1914.
105. [105] Noguera-Troise, I., Daly, C., Papadopoulos, N.J., Coetzee, S., Boland, P., Gale, N.W., et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444 (2006), 1032–1037.
106. [106] Ridgway, J., Zhang, G., Wu, Y., Stawicki, S., Liang, W.C., Chanthery, Y., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444 (2006), 1083–1087.
107. [107] Niels, U., Chinot, O., McBain, C., Sorensen, M., Larsen, V., Barrie, M., et al. Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM). American Society of Clinical Oncology Annual Meeting, 2013 Chicago, IL.
108. [108] Ostman, A., Heldin, C.H., PDGF receptors as targets in tumor treatment. Adv. Cancer Res 97 (2007), 247–274.
109. [109] Kampa-Schittenhelm, K.M., Heinrich, M.C., Akmut, F., Döhner, H., Döhner, K., Schittenhelm, M.M., Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol. Cancer, 12, 2013, 19.
110. [110] Xi, Y., Chen, M., Liu, X., Lu, Z., Ding, Y., Li, D., CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and migration. Onco. Targets Ther 7 (2014), 1215–1221.
111. [111] Soh, C.L., McNeil, K., Owczarek, C.M., Hardy, M.P., Fabri, L.J., Pearse, M., et al. Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer. Br. J. Cancer 110 (2014), 2855–2864.
112. [112] Elice, F., Rodeghiero, F., Side effects of anti-angiogenic drugs. Thromb. Res 129:Suppl. 1 (2012), S50–S53.
113. [113] Hayman, S.R., Leung, N., Grande, J.P., Garovic, V.D., VEGF inhibition, hypertension, and renal toxicity. Curr. Oncol. Rep 14 (2012), 285–294.
114. [114] Pralhad, T., Madhusudan, S., Rajendrakumar, K., Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J. Pharm. Pharmacol 55 (2003), 1045–1053.
115. [115] Molnar, N., Siemann, D.W., Combined Ang-2 and VEGF targeting therapies in renal cell carcinoma. J. Cancer Ther 4 (2013), 1–6.
116. [116] Brown, J.L., Cao, Z.A., Pinzon-Ortiz, M., Kendrew, J., Reimer, C., Wen, S., et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol. Cancer Ther 9 (2010), 145–156.
117. [117] Wilhelm, S.M., Dumas, J., Adnane, L., Lynch, M., Carter, C.A., Schutz, G., et al. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129 (2011), 245–255.
118. [118] Koh, Y.J., Kim, H.Z., Hwang, S.I., Lee, J.E., Oh, N., Jung, K., et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18 (2010), 171–184.
119. [119] Kienast, Y., Klein, C., Scheuer, W., Raemsch, R., Lorenzon, E., Bernicke, D., et al. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin. Cancer Res 19 (2013), 6730–6740.
120. [120] Hidalgo, M., Le Tourneau, C., Massard, C., Boni, V., Calvo, E., Albanell, J., et al. Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-Ang-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors. American Society of Clinical Oncology Annual Meeting, 2014 Chicago, IL.
121. [121] Bristow, R.G., Hill, R.P., Molecular and Cellular Basis of Radiotherapy. Hill, R., Tannock, I.F., Bristow, R.G., Harrington, L., (eds.) The Basic Science of Oncology, 2005, McGraw-Hill Medical Publishing Division.
122. [122] Giaccia, A.J., Hall, E.J., Cell survival curves. Giaccia, A.J., Hall, E.J., (eds.) Radiobiology for the Radiologist, 2006, Lippincott Williams and Wilkins, Philadelphia PA.
123. [123] Vogel, J., Camphausen, K., Angiogenesis inhibitors and radiation in multimodality cancer therapy: preclinical and clinical studies. Curr. Angiogenes 1 (2012), 157–167.
124. [124] Schmidt, B., Lee, H.J., Ryeom, S., Yoon, S.S., Combining bevacizumab with radiation or chemoradiation for solid tumors: a review of the scientific rationale, and clinical trials. Curr. Angiogenes 1 (2012), 169–179.
125. [125] Dings, R.P., Loren, M., Heun, H., McNiel, E., Griffioen, A.W., Mayo, K.H., et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res 13 (2007), 3395–3402.
126. [126] Geng, L., Donnelly, E., McMahon, G., Lin, P.C., Sierra-Rivera, E., Oshinka, H., et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61 (2001), 2413–2419.
127. [127] Siemann, D.W., Shi, W., Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int. J. Radiat. Oncol. Biol. Phys 60 (2004), 1233–1240.
128. [128] Shaked, Y., Nathan, P., Daenen, L.G.M., Kerbel, R.S., Combining antiangiogenic drugs with vascular disrupting agents rationale and mechanisms of action. Meyer, T., (eds.) Vascular Disruptive Agents for the Treatment of Cancer, 2010, Springer Science + Business Media LLC, New York.
129. [129] Siemann, D.W., Bibby, M.C., Dark, G.G., Dicker, A.P., Eskens, F.A., Horsman, M.R., et al. Differentiation and definition of vascular-targeted therapies. Clin. Cancer Res 11 (2005), 416–420.
130. [130] Siemann, D.W., Chaplin, D.J., Horsman, M.R., Vascular-targeting therapies for treatment of malignant disease. Cancer 100 (2004), 2491–2499.
131. [131] Siemann, D.W., Shi, W., Dual targeting of tumor vasculature: combining avastin and vascular disrupting agents (Ca4P or Oxi4503). Anticancer Res 28 (2008), 2027–2032.
132. [132] Chen, F., Feng, Y., Zheng, K., De Keyzer, F., Li, J., Feng, Y., et al. Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI. PLoS ONE, 7, 2012, e41140.
133. [133] Nathan, P., Zweifel, M., Padhani, A.R., Koh, D.M., Ng, M., Collins, D.J., et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin. Cancer Res 18 (2012), 3428–3439.
134. [134] Welford, A.F., Biziato, D., Coffelt, S.B., Nucera, S., Fisher, M., Pucci, F., et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest 121 (2011), 1969–1973.